News

The primary outcome of the study which randomized 430 participants across three treatment arms placebo, 5mg or the currently marketed dose of 10mg of dalfampridine-ER, twice daily, was

ScripsAmerica’s manufacturer is expected to begin production of the RapiMed formulations and make the product available for distribution during the first quarter of 2013. ScripsAmerica CEO Bob Schneiderman

The company is seeking approval to manufacture and market Quartette (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets), the first ascending-dose, extended regimen oral contraceptive for the prevention of

Symbicort Turbuhaler is a combination product containing a long-acting ß2 agonist with a bronchodilating action that is the mainstay of drug-based COPD therapy, and an inhaled corticosteroid, which

The services include IT strategy and planning, electronic health record (EHR) implementation and optimization, and management consulting across a broad range of activities such as accountable care transformation.

Nexium (esomeprazole magnesium) is a prescription drug currently approved to treat the symptoms of gastroesophageal reflux disease (GERD). Pfizer consumer healthcare president Paul Sturman said, "By working with

EoE is a chronic disease characterized by symptoms related to esophageal dysfunction and eosinophil-predominant inflammation. The 16-week study will enroll about 100 patients at multiple US clinical centers

The trial reportedly did not meet its primary endpoint of superiority in extending progression free survival (PFS). Pfizer Oncology Business Unit senior vice president of clinical development and

MCT-465 and MCT-485 are cancer therapeutics, which use TLR3 signaling technology. During the trials, MCT-485 showed in vitro dose-effect cytotoxicity on several human hepatocellular carcinoma cell lines while